PDCD1 and cancer: However, the incidence of HBVr in cancer patients with ongoing PD-1 inhibitor combination therapies remains unclear, and more research is needed to validate the relationship between PD-1 inhibitors and immune-mediated clearance of HBV or serum HBsAg clearance in this context.